Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2023

27-11-2022 | Soft Tissue Tumor | Sarcoma

Epidemiologic Survey of Myxofibrosarcoma Using Data from the Bone and Soft Tissue Tumor Registry in Japan

Authors: Satoshi Kamio, MD, Morio Matsumoto, MD, PhD, Masaya Nakamura, MD, PhD, Akira Kawai, MD, PhD, Kazutaka Kikuta, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2023

Login to get access

Abstract

Background

Myxofibrosarcoma is a common sarcoma among older patients, with locally infiltrative behavior and a predilection for local postoperative recurrence. Some studies have reported the factors affecting prognosis, although only a few have mentioned the previous staging classification systems. This study investigated the clinical overview and prognosis of myxofibrosarcoma to determine the optimal treatment.

Methods

This retrospective study analyzed the records of 349 patients with myxofibrosarcoma in the nationwide Bone and Soft Tissue Tumor Registry in Japan from 2006 to 2015. Clinical features, treatment options, and patient outcomes were investigated.

Results

Ultimately, 349 patients were identified. The overall survival rates were 93.1% at 2 years and 84.3% at 5 years. A multivariate analysis was performed using the Cox proportional hazards model. The study identified four significant prognostic factors for survival: tumor size, depth, compartment status, and location. The prognostic score was calculated by summing the scores of all the factors. The overall survival rate was 69.3% at 5 years for the patients with prognostic scores of 6 or higher. Conversely, the patients with prognostic scores of 2 or lower had a survival rate of 95.6% at 5 years.

Conclusions

Among myxofibrosarcomas, those larger than 5 cm, deep-seated, invaded into the external compartment, or in axial body parts were associated with a significantly worse prognosis. Adjuvant radiotherapy and chemotherapy did not contribute significantly to a better prognosis. Previous staging classification systems are impractical for prognosis prediction. Therefore, new classifications are needed. Further research on new treatment methods for patients with a poor prognosis will be crucial in the future.
Literature
1.
Mentzel T, van de Berg D, Molenaar WM. Myxofibrosarcoma. In: CDM Fletcher, KK Unni, F Mertens, editors. WHO classification of tumors-Pathology and genetics, Tumors of soft tissue and bone. Lyon: IARC Press; 2002. p. 102–3.
2.
Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672–85.CrossRefPubMed
3.
Angervall L, Kindblom LG, Merck C. Myxofibrosarcoma: a study of 30 cases. Acta Pathol Microbiol Scand A. 1977;85A:127–40.PubMed
4.
Fletcher CD, Hogendoorn P, Mertens F, et al. WHO Classification of tumours of soft tissue and bone. 4th edn. Lyon, France: IARC Press; 2013.
5.
Roland CL, Wang WL, Lazar AJ, Torres KE. Myxofibrosarcoma. Surg Oncol Clin North Am. 2016;25(775):788.
6.
Merck C, Angervall L, Kindblom LG, Odén A. Myxofibrosarcoma a malignant soft tissue tumor of fibroblastic-histiocytic origin: a clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta Pathol Microbiol Immunol Scand. 1983;282(Suppl):1–40.
7.
Waters B, Panicek DM, Lefkowitz RA, et al. Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease. AJR Am J Roentgenol. 2007;188:W193–8.CrossRefPubMed
8.
Manoso MW, Pratt J, Healey JH, Boland PJ, Athanasian EA. Infiltrative MRI pattern and incomplete initial surgery compromise local control of myxofibrosarcoma. Clin Orthop Relat Res. 2006;450:89–94.CrossRefPubMed
9.
Kikuta K, Kubota D, Yoshida A, et al. An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI. Skeletal Radiol. 2015;44:55–62.CrossRefPubMed
10.
Kaya M, Wada T, Nagoya S, et al. MRI and histological evaluation of the infiltrative growth pattern of myxofibrosarcoma. Skeletal Radiol. 2008;37:1085–90.CrossRefPubMed
11.
Kikuta K, Kubota D, Yoshida A, et al. An analysis of factors related to recurrence of myxofibrosarcoma. Jpn J Clin Oncol. 2013;43:1093–104.CrossRefPubMed
12.
Widemann BC, Italiano A. Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumors: state of the art and perspectives. J Clin Oncol. 2018;36:160–7.CrossRefPubMed
13.
Sanfilippo R, Miceli R, Grosso F, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011;18:720–5.CrossRefPubMed
14.
Haglund KE, Raut CP, Nascimento AF, et al. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2012;82:361–7.CrossRefPubMed
15.
Teurneau H, Engellau J, Ghanei I, Vult von Steyern F, Styring E. High recurrence rate of myxofibrosarcoma: the effect of radiotherapy is not clear. Sarcoma. 2019;2019:1–8.CrossRef
16.
Edge S, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th edn. New York: Springer; 2010.
17.
Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.CrossRef
18.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
19.
Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972;34:187–202.
20.
Sambri A, Spinnato P, Bazzocchi A, et al. Does preoperative MRI predict the risk of local recurrence in primary myxofibrosarcoma of the extremities? Asia Pac J Clin Oncol. 2019;15:e181–6.CrossRefPubMed
21.
Gronchi A, Lo Vullo S, Colombo C, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg. 2010;251:506–11.CrossRefPubMed
22.
Fletcher CD, Gustafson P, Rydholm A, Willén H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001;19:3045–50.CrossRefPubMed
23.
Look Hong NJ, Hornicek FJ, Raskin KA, et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013;20:80–6.CrossRefPubMed
24.
Gilg MM, Sunitsch S, Leitner L, et al. Tumor-associated mortality and prognostic factors in myxofibrosarcoma: a retrospective review of 109 patients. Orthop Traumatol Surg Res. 2020;106:1059–65.CrossRefPubMed
25.
Lin CN, Chou SC, Li CF, et al. Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol. 2006;93:294–303.CrossRefPubMed
26.
Odei B, Rwigema JC, Eilber FR, et al. Predictors of local recurrence in patients with myxofibrosarcoma. Am J Clin Oncol. 2018;41:827–31.CrossRefPubMed
27.
Dadrass F, Gusho C, Yang F, et al. A clinicopathologic examination of myxofibrosarcoma: do surgical margins significantly affect local recurrence rates in this infiltrative sarcoma subtype? J Surg Oncol. 2021;123:489–96.CrossRefPubMed
28.
Ghazala CG, Agni NR, Ragbir M, et al. Myxofibrosarcoma of the extremity and trunk: a multidisciplinary approach leads to good local rates of LOCAL control. Bone Joint J. 2016;98B:1682–8.CrossRef
29.
Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol. 2004;35:612–21.CrossRefPubMed
30.
Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma: clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996;20:391–405.CrossRefPubMed
31.
32.
Sambri A, Tuzzato G, Spinnato P, et al. Grading in myxofibrosarcoma of the extremities can predict survival and local control. Oncol Res Treat. 2020;43:189–95.CrossRefPubMed
33.
Hambleton C, Noureldine S, Gill F, Moroz K, Kandil E. Myxofibrosarcoma with metastasis to the lungs, pleura, and mediastinum: a case report and review of literature. Int J Clin Exp Med. 2012;5:92–5.PubMedPubMedCentral
34.
Mutter RW, Singer S, Zhang Z, Brennan MF, Alektiar KM. The enigma of myxofibrosarcoma of the extremity. Cancer. 2012;118:518–27.CrossRefPubMed
35.
Boughzala-Bennadji R, Stoeckle E, Le Péchoux CL, et al. Localized myxofibrosarcomas: roles of surgical margins and adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2018;102:399–406.CrossRefPubMed
36.
Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th edn. New York: Springer; 2017.CrossRef
37.
Smolle MA, van de Sande M, Hayes A, et al. Comparison of the 7th and 8th versions of the AJCC classification system for soft tissue sarcomas of extremities and trunk in patients with localized, intermediate- or high-grade disease treated at European tertiary sarcoma centres. Eur J Surg Oncol. 2021;47:2182–8.CrossRefPubMed
38.
Cates JMM. Performance analysis of the American Joint Committee on Cancer 8th-edition staging system for retroperitoneal sarcoma and development of a new staging algorithm for sarcoma-specific survival. Ann Surg Oncol. 2017;24:3880–7.CrossRefPubMed
Metadata
Title
Epidemiologic Survey of Myxofibrosarcoma Using Data from the Bone and Soft Tissue Tumor Registry in Japan
Authors
Satoshi Kamio, MD
Morio Matsumoto, MD, PhD
Masaya Nakamura, MD, PhD
Akira Kawai, MD, PhD
Kazutaka Kikuta, MD, PhD
Publication date
27-11-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12868-4

Other articles of this Issue 5/2023

Annals of Surgical Oncology 5/2023 Go to the issue

Translational Research

Hypoxia-Induced CD36 Expression in Gastric Cancer Cells Promotes Peritoneal Metastasis via Fatty Acid Uptake

ASO Author Reflections

ASO Author Reflections: Patient-Reported Outcomes of the CAIRO6 Phase II Trial

Thoracic Oncology

Is Thoracic Duct Resection Necessary for Esophageal Squamous Cell Carcinoma Patients Treated with Neoadjuvant Chemoradiotherapy? A Propensity-Matched Analysis Based on the Comprehensive Registry of Esophageal Cancer in Japan

Gastrointestinal Oncology

Transgastric Single-Incision Laparoscopic Resection for a Gastric Submucosal Tumor Located at the Cardia

Peritoneal Surface Malignancy

Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center

Hepatobiliary Tumors

The Prognostic Value of Preoperative Serum Markers and Risk Classification in Patients with Hepatocellular Carcinoma